Ads
related to: decitabine dose in aml- FAQ Page
Additional Questions? Visit Our FAQ
Page For More Information.
- Dosing & Management
Learn About Dosing For
R/R Myelodysplastic Syndromes.
- Safety Information
HCPs - Read The Safety Profile Of
This R/R MDS Treatment Option.
- R/R MDS Efficacy
See Clinical Data About
This R/R MDS Treatment Option.
- Connect with a Rep
Schedule an Appointment with
A Representative Today
- Access & Resources
HCPs - More Information & Resources
Are Available For You Here.
- FAQ Page
Search results
Results From The WOW.Com Content Network
Decitabine/cedazuridine is indicated for treatment of adults with myelodysplastic syndromes, including previously treated and untreated, de novo and secondary myelodysplastic syndromes with the following French American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia) and intermediate-1 ...
Decitabine (i.e., 5-aza-2′-deoxycytidine), sold under the brand name Dacogen among others, acts as a nucleic acid synthesis inhibitor. [4] It is a medication for the treatment of myelodysplastic syndromes, a class of conditions where certain blood cells are dysfunctional, and for acute myeloid leukemia (AML). [5] Chemically, it is a cytidine ...
Venetoclax is also indicated as part of a combination therapy for acute myeloid leukemia (AML). [7] For this purpose it is used with azacitidine, decitabine, or low-dose cytarabine for newly diagnosed adults who are age 75 years or older, or those with other health problems where intensive chemotherapy cannot be used.
High dose: cerebral and cerebellar dysfunction, ocular toxicity, pulmonary toxicity, severe GI ulceration and peripheral neuropathy (rare). Decitabine: IV: DNA methyltransferase inhibitor. Myelodysplastic syndrome, sickle cell anaemia (orphan), acute myeloid leukaemia and chronic myeloid leukaemia.
Azacitidine is indicated for the treatment of myelodysplastic syndrome, [4] for which it received approval by the U.S. Food and Drug Administration (FDA) on 19 May 2004. [11] [4] [12] In two randomized controlled trials comparing azacitidine to supportive treatment, 16% of subjects with myelodysplastic syndrome who were randomized to receive azacitidine had a complete or partial normalization ...
A hypomethylating agent (or demethylating agent [1]) is a drug that inhibits DNA methylation: the modification of DNA nucleotides by addition of a methyl group.Because DNA methylation affects cellular function through successive generations of cells without changing the underlying DNA sequence, treatment with a hypomethylating agent is considered a type of epigenetic therapy.
Ads
related to: decitabine dose in aml